Glenmark enters $25M US market with generic Olanzapine injection

Glenmark Pharmaceuticals launched a generic version of Olanzapine injection in the US on Monday, targeting the $25.4 million annual market for Zyprexa intramuscular injections. The company disclosed the launch in a regulatory filing. The product is indicated for acute treatment of agitation in schizophrenia and bipolar I disorder.

Glenmark's Olanzapine for injection comes in a 10 mg per vial single-dose vial. It is bioequivalent to the branded reference drug, Zyprexa, marketed by Cheplapharm Registration GmbH. The company's US arm, Glenmark Pharmaceuticals Inc., USA, is handling the commercial launch.

Marc Kikuchi, president and business head of North America at Glenmark, framed the launch as part of a broader strategy. "The launch of Olanzapine for Injection underscores our strategic focus on growing a robust injectables portfolio and strengthening our presence within the institutional channel," he said.

The $25.4 million annual sales figure comes from IQVIA data for the 12 months ended May 2026. It reflects the brand-name Zyprexa IM market, now open to generic competition.

For Glenmark, the product is a small bet. A $25 million market, even at a high single-digit share, adds at most a few million dollars in revenue. With this launch, Glenmark pushes deeper into injectable generics, a higher-margin category than oral solids. Hospital contracts in this channel lock in multiyear volumes.

Cheplapharm, the brand owner, faces a price drop as generic entrants vie for formulary slots. Glenmark moves first here. The filing omits any mention of first-to-file exclusivity. No other approved generics for this strength appear in the filing.